<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191762</url>
  </required_header>
  <id_info>
    <org_study_id>PhelpsK</org_study_id>
    <nct_id>NCT01191762</nct_id>
  </id_info>
  <brief_title>Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth R. Phelps, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phelps, Kenneth R., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium
      reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain
      normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures
      of phosphate homeostasis and calcium reabsorption. A double-blind trial of the intestinal
      phosphate binder sevelamer carbonate will be employed to examine whether reductions in
      phosphate influx alter distal nephron phosphate concentration and the [PTH] required for
      calcium reabsorption in the expected manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The parathyroid hormone concentration ([PTH)] rises as glomerular filtration rate (GFR)
      falls. This almost universal phenomenon is called secondary hyperparathyroidism (SHPT). [PTH]
      rises with dietary phosphate in chronic kidney disease. [PTH] also rises with stable dietary
      phosphate as GFR falls. The mechanism underlying these phenomena is unknown.

      We hypothesize that phosphate exerts its effect on [PTH] in the cortical distal nephron
      (CDN). Ordinarily, intestinal phosphate absorption does not fall in proportion to GFR as
      chronic kidney disease (CKD) progresses. Consequently, the concentration of phosphate
      increases in the cortical distal nephron (CDN), where PTH regulates tubular calcium
      reabsorption. We speculate that increased [P]cdn reduces the concentration of free calcium
      through complexation, and thereby necessitates high [PTH] for achievement of calcium
      reabsorption sufficient to maintain normocalcemia. We can show algebraically that [P]cdn is
      proportional to the ratio EP/Ccr, where EP is the urinary excretion rate of phosphate and Ccr
      is creatinine clearance, a surrogate for GFR. EP/Ccr can be calculated from measurements in
      aliquots of serum and urine as [P]u[cr]s/[cr]u. If our hypothesis is correct, we anticipate
      that [PTH] will be proportional to EP/Ccr in CKD, and that delta [PTH] will be proportional
      to delta EP/Ccr obtained with sequential determinations.

      We will study 30 patients with CKD and a comparable number of controls. All subjects will
      have normocalcemia. Controls will be seen once for informed consent, and once in the fasting
      state between 8:00 a.m. and 10:00 a.m. for collection of urine and blood specimens.

      Patients with CKD will be seen at five visits at intervals of four weeks. At the first visit,
      we will obtain informed consent and obtain a specimen for measurement of 25-hydroxyvitamin D
      (25OHD). At visits 2-5, we will obtain necessary specimens to measure concentrations of PTH,
      fibroblast growth factor 23 (FGF23), 25OHD, and 1,25-dihyroxyvitamin D (1,25(OH)2D). We will
      also measure ionized and ultrafilterable calcium, creatinine, and phosphorus in serum and
      calcium, phosphorus, and creatinine in urine. These measurements will enable us to follow the
      effects of interventions on hormone concentrations and parameters of calcium and phosphorus
      homeostasis.

      At visit 2 we will prescribe vitamin D in accordance with [25OHD] obtained at visit 1. For
      [25OHD] &lt; 32 ng/mL, doses will be 50,000 units/d of D2 for one week, followed by 2000 mg/d of
      D2 for 3 weeks. For [25OHD] &gt; 32 ng/mL, the dose will be D3 2000 mg/d for four weeks. The
      purpose of this intervention is to minimize the likelihood that vitamin D insufficiency or
      deficiency contributes to SHPT.

      At visit 3, we will instruct patients in a phosphate-restricted diet. At visit 4 we will
      quantify the metabolic effects of the diet, and will randomly assign patients to receive
      either placebo or sevelamer carbonate 800 mg tablets, 3 with each meal. At visit 5, we will
      quantify the effects of the two interventions on parameters of calcium and phosphate
      homeostasis and on hormone concentrations. We will view positive regressions of [PTH] on
      EP/Ccr and of ∆[PTH] on ∆EP/Ccr as evidence for our hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</measure>
    <time_frame>4 weeks</time_frame>
    <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hyperparathyroidism</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>sevelamer carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400 mg (3 pills) with each meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer carbonate</intervention_name>
    <description>2400 mg with each meal for 4 weeks</description>
    <arm_group_label>sevelamer carbonate</arm_group_label>
    <other_name>Renvela (Genzyme)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 tablets with each meal</description>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eGFR &lt; 60 ml/min

          -  age at least 18 years

        Exclusion Criteria:

          -  any primary parathyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth R. Phelps, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stratton VAMC, Albany, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stratton Veterans Affairs Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <results_first_submitted>November 13, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2014</results_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Phelps, Kenneth R., M.D.</investigator_affiliation>
    <investigator_full_name>Kenneth R. Phelps, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>secondary hyperparathyroidism</keyword>
  <keyword>phosphate</keyword>
  <keyword>calcium</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with eGFR &lt; 60 were recruited from renal clinics and randomized to receive 3 tablets of sevelamer or placebo with each meal for four weeks.</recruitment_details>
      <pre_assignment_details>Randomization was preceded by a 4-week course of vitamin D (dose determined by plasma [25OHD]) and then by a 4-week period of dietary phosphate restriction. The phosphate restriction was continued through the therapeutic trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">One subject dropped out on the 3rd treatment day because of gastrointestinal complaints.</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Post-treatment data were not obtained from patient who withdrew on third treatment day.</population>
      <group_list>
        <group group_id="B1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.7" spread="8.5"/>
                    <measurement group_id="B2" value="70.1" spread="10.5"/>
                    <measurement group_id="B3" value="71.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</title>
        <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate</title>
            <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</title>
          <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
          <units>percentage of baseline [PTH]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="5.8"/>
                    <measurement group_id="O2" value="16.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>The patient complained of nausea and upset stomach from the inception of his treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All intended measurements were made. The desired number of participants was recruited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kenneth R. Phelps, M.D.</name_or_title>
      <organization>Kenneth R. Phelps, M.D.</organization>
      <phone>518-626-5641</phone>
      <email>kenneth.phelps@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

